Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Clearmind Medicine Inc. < Previous 1 2 Next > Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment June 28, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment June 20, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink June 11, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product May 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment May 07, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Applies to Cease Being a Reporting Issuer in Canada April 30, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders April 17, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders April 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine CEO Issues Letter to Shareholders April 09, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression March 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China March 19, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND SPRC Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder February 23, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds February 20, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND SPRC Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China February 05, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center February 01, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement January 16, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement January 11, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Completed Type A Meeting with the FDA January 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments January 04, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND SPRC Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards December 14, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment December 05, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial December 01, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment November 28, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures November 27, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Announces 1-for-30 Reverse Share Split November 21, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance November 17, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND Clearmind Medicine Announces Shareholders Meeting Results November 15, 2023 From Clearmind Medicine Inc. Via GlobeNewswire Tickers CMND CSE:CMND < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.